Revenue grew 4% in H1, with strong order book and pilots supporting a reiterated 50% full-year growth target. Major partnerships expanded, new contracts secured, and US market entry advanced with the New York lab permit. H2 focus is on targeted sales and commercial scaling.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.